Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

ME. Hyndman, RJ. Paproski, A. Kinnaird, A. Fairey, L. Marks, CP. Pavlovich, SA. Fletcher, R. Zachoval, V. Adamcova, J. Stejskal, A. Aprikian, CJD. Wallis, D. Pink, C. Vasquez, PH. Beatty, JD. Lewis

. 2024 ; 7 (1) : 163. [pub] 20240620

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24012516

Grant support
G2017000328 Alberta Innovates
ACF 26001 Alberta Cancer Foundation
PCC MTA TAG2014-03 Prostate Cancer Canada (Cancer de la Prostate Canada)

The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa. Integrating the ClarityDX platform with blood-based biomarkers for clinically significant PCa and clinical biomarker data from a 3448-patient cohort, we developed a test to stratify patients' risk of csPCa; called ClarityDX Prostate. When predicting high risk cancer in the validation cohort, ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value, at a ≥ 25% threshold. Using ClarityDX Prostate at this threshold could avoid up to 35% of unnecessary prostate biopsies. ClarityDX Prostate showed higher accuracy for predicting the risk of csPCa than PSA alone and the tested model-based risk calculators. Using this test as a reflex test in men with elevated PSA levels may help patients and their healthcare providers decide if a prostate biopsy is necessary.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012516
003      
CZ-PrNML
005      
20240726151409.0
007      
ta
008      
240723s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41746-024-01167-9 $2 doi
035    __
$a (PubMed)38902526
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hyndman, M Eric $u Department of Surgical Oncology, University of Calgary, Prostate Cancer Centre, Calgary, T2P 1P9, AB, Canada $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada
245    10
$a Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform / $c ME. Hyndman, RJ. Paproski, A. Kinnaird, A. Fairey, L. Marks, CP. Pavlovich, SA. Fletcher, R. Zachoval, V. Adamcova, J. Stejskal, A. Aprikian, CJD. Wallis, D. Pink, C. Vasquez, PH. Beatty, JD. Lewis
520    9_
$a The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa. Integrating the ClarityDX platform with blood-based biomarkers for clinically significant PCa and clinical biomarker data from a 3448-patient cohort, we developed a test to stratify patients' risk of csPCa; called ClarityDX Prostate. When predicting high risk cancer in the validation cohort, ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value, at a ≥ 25% threshold. Using ClarityDX Prostate at this threshold could avoid up to 35% of unnecessary prostate biopsies. ClarityDX Prostate showed higher accuracy for predicting the risk of csPCa than PSA alone and the tested model-based risk calculators. Using this test as a reflex test in men with elevated PSA levels may help patients and their healthcare providers decide if a prostate biopsy is necessary.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Paproski, Robert J $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada
700    1_
$a Kinnaird, Adam $u Division of Urology, Department of Surgery, University of Alberta, Kipnes Urology Centre, Edmonton, T6G 1Z1, AB, Canada $u Department of Oncology, University of Alberta, Edmonton, T6G 2E1, AB, Canada
700    1_
$a Fairey, Adrian $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada $u Division of Urology, Department of Surgery, University of Alberta, Kipnes Urology Centre, Edmonton, T6G 1Z1, AB, Canada
700    1_
$a Marks, Leonard $u UCLA Health, Westwood Urology 200 Medical Plaza, Suite 140, Los Angeles, CA, 90095, USA
700    1_
$a Pavlovich, Christian P $u James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, 21287, MD, USA
700    1_
$a Fletcher, Sean A $u James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, 21287, MD, USA
700    1_
$a Zachoval, Roman $u Department of Urology, 3rd Faculty of Medicine of Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Adamcova, Vanda $u Department of Urology, 3rd Faculty of Medicine of Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Stejskal, Jiri $u Department of Urology, 3rd Faculty of Medicine of Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Aprikian, Armen $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada $u Department of Surgery, McGill University, Montreal, H3G 2M1, QC, Canada
700    1_
$a Wallis, Christopher J D $u Division of Urology, Department of Surgery, University of Toronto, Toronto, M5T 1P5, ON, Canada $u Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, M5G 1X5, ON, Canada $u Department of Surgical Oncology, University Health Network, Toronto, ON, Canada $1 https://orcid.org/0000000259904026
700    1_
$a Pink, Desmond $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada
700    1_
$a Vasquez, Catalina $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada
700    1_
$a Beatty, Perrin H $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada
700    1_
$a Lewis, John D $u Nanostics Inc., 4550 10230 Jasper Avenue, Edmonton, T5J 4P6, AB, Canada. jdlewis@ualberta.ca $u Department of Oncology, University of Alberta, Edmonton, T6G 2E1, AB, Canada. jdlewis@ualberta.ca $1 https://orcid.org/0000000277341204
773    0_
$w MED00209727 $t NPJ digital medicine $x 2398-6352 $g Roč. 7, č. 1 (2024), s. 163
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38902526 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151402 $b ABA008
999    __
$a ok $b bmc $g 2125396 $s 1224379
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 7 $c 1 $d 163 $e 20240620 $i 2398-6352 $m NPJ digital medicine $n NPJ Digit Med $x MED00209727
GRA    __
$a G2017000328 $p Alberta Innovates
GRA    __
$a ACF 26001 $p Alberta Cancer Foundation
GRA    __
$a PCC MTA TAG2014-03 $p Prostate Cancer Canada (Cancer de la Prostate Canada)
LZP    __
$a Pubmed-20240723

Find record

Citation metrics

Archiving options